Qualia NAD+(R) Increases NAD+, Improves Well-Being, and Alleviates Aging Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study
Blomquist, S.; Kelly, G.; Adaes, S.; Ardagh, A.; Ramer, S.; Scuba, W.
Show abstract
A key factor in aging and many age-related diseases is the decline in nicotinamide adenine dinucleotide (NAD+) levels. Preclinical studies demonstrate promising results for NAD+ boosting in improving conditions of disease or aging. However, only a limited number of human studies have shown meaningful improvements in physiological function or quality of life with NAD+ boosting supplements. This randomized, double-blind, placebo-controlled study (Clinicaltrails.gov identifier: NCT06505967) investigated the impact of Qualia NAD+(R), a novel NAD+ supporting nutraceutical containing nicotinamide riboside (NR) and a variety of synergistic vitamins, minerals, and botanicals, on blood NAD+ levels and healthy aging, as assessed by quality of life surveys. MethodsStudy participants were randomly allocated to consume either Qualia NAD+ or placebo for 28 days. NAD+ levels were measured at baseline and study end using a validated, self-administered, dried blood spot assay. Quality of life measures were assessed weekly. Independent samples t-tests were used to compare NAD+ levels between study arms. Questionnaire data were compared using linear mixed-effects regression modeling. ResultsSixty-three healthy adults (n = 28 Qualia NAD+, n=35 placebo) enrolled in the study and had their NAD+ levels assessed. Qualia NAD+ increased NAD+ levels by 67% compared to 4% with placebo (p < 0.001). Qualia NAD+ improved emotional well-being versus placebo at multiple timepoints (p < 0.05). Aging female symptoms improved in overall and somatic categories at day 28 (p < 0.05). No improvements in aging symptoms were observed for males. ConclusionsQualia NAD+ increased NAD+ levels, enhanced quality of life in all participants, and alleviated some aging symptoms in females greater than placebo. The increase in NAD+ levels with Qualia NAD+ was greater than in most previous clinical trials of NAD+ supporting products at similar dosing, suggesting potential synergy between NR and the complementary nutrients in the product.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.